Skin from horses with hereditary equine regional dermal asthenia (HERDA) contains collagen crosslinking patterns that are associated with reduced tensile strength by Hill, Ashley Arwen
Mississippi State University 
Scholars Junction 
Theses and Dissertations Theses and Dissertations 
8-7-2010 
Skin from horses with hereditary equine regional dermal asthenia 
(HERDA) contains collagen crosslinking patterns that are 
associated with reduced tensile strength 
Ashley Arwen Hill 
Follow this and additional works at: https://scholarsjunction.msstate.edu/td 
Recommended Citation 
Hill, Ashley Arwen, "Skin from horses with hereditary equine regional dermal asthenia (HERDA) contains 
collagen crosslinking patterns that are associated with reduced tensile strength" (2010). Theses and 
Dissertations. 3962. 
https://scholarsjunction.msstate.edu/td/3962 
This Graduate Thesis - Open Access is brought to you for free and open access by the Theses and Dissertations at 
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of 
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com. 
Template Created By: James Nail 2010 
SKIN FROM HORSES WITH HEREDITARY EQUINE REGIONAL DERMAL 
ASTHENIA (HERDA) CONTAINS COLLAGEN CROSSLINKING  
PATTERNS THAT ARE ASSOCIATED WITH REDUCED  
TENSILE STRENGTH 
By 
Ashley Arwen Hill 
A Thesis 
Submitted to the Faculty of 
Mississippi State University 
in Partial Fulfillment of the Requirements 
for the Degree of Master of Science 
in Veterinary Medical Science 
in the Department of Clinical Sciences,College of Veterinary Medicine 
Mississippi State, Mississippi 
August 2010 
Template Created By: James Nail 2010 
Copyright 5BAugust 2010 
By 
Ashley Arwen Hill 
Template Created By: James Nail 2010 
SKIN FROM HORSES WITH HEREDITARY EQUINE REGIONAL DERMAL 
ASTHENIA (HERDA) CONTAINS COLLAGEN CROSSLINKING  










Marzia Pasquali Ron McLaughlin 
Professor of Pathology, Professor and Chief 
University of Utah School of Medicine Head of Department of Clinical Sciences 




Shane C. Burgess Hart Bailey 
Professor, Associate Professor, 
Department of Basic Sciences Department of Pathobiology and Population 
(Committee Member) Medicine   




Cyprianna Swiderski Kent Hoblet 
Assistant Professor, Dean of the College of Veterinary Medicine 
Department of Clinical Sciences 
(Graduate Coordinator) 
Template Created By: James Nail 2010 
Name: Ashley Arwen Hill 
 
Date of Degree: 5BAugust 2010 
 
Institution: Mississippi State University 
 
Major Field: Veterinary Medical Science 
 
Major Professor: Dr. Cyprianna Swiderski 
 
Title of Study:    SKIN FROM HORSES WITH HEREDITARY EQUINE REGIONAL 
DERMAL ASTHENIA (HERDA) CONTAINS COLLAGEN 
CROSSLINKING PATTERNS THAT ARE ASSOCIATED WITH 
REDUCED TENSILE STRENGTH 
 
Pages in Study: 39 
 
Candidate for Degree of Master of Science 
 
Hereditary equine regional dermal asthenia (HERDA) is a recessive connective 
tissue disorder of Quarter Horse lineages.  This study correlates previously identified 
decreases in skin tensile strength in HERDA with abnormal dermal collagen cross linking 
patterns that are also identified in urine from HERDA horses.  Dermal collagen from 
HERDA horses has significantly less pyridinoline and significantly more 
deoxypyridinoline than control or carriers. Concentrations of hydroxylysine, the rate 
limiting substrate for these crosslinks were significantly lower in HERDA versus control 
and carriers. These characteristics of HERDA skin parallel humans with a similar 
syndrome of skin fragility, Ehlers Danlos Syndrome TypeVIA. This is the first 
biochemical evidence explaining the clinical skin fragility that characterizes HERDA and 
suggests that altered collagen lysine metabolism may be physiologically relevant to the 
clinical manifestation of HERDA.  Evaluations of mature scars indicate that lesion and 
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Hereditary equine regional dermal asthenia (HERDA), also known as 
hyperelastosis cutis (HC) is an autosomal recessive connective tissue disorder, first 
described in 1978, that affects Quarter Horses or horses of Quarter Horse lineage.1,2  The 
skin of affected horses has been described as feeling ‘doughy’ or ‘mushy’ to the touch 
with areas that are poorly attached and hyperextensible, and other areas that are fragile 
and thin. Skin lesions, including subcutaneous hematomas and open wounds occur from 
normally innocuous contact, especially along the dorsum.3  These wounds, which are 
slow to heal, result in disfiguring scars.4  A horse affected by HERDA cannot be ridden 
or shown competitively and most are humanely euthanized.  Prior to the availability of a 
DNA test in 2007 that identifies horses with HERDA, the condition was recognized when 
lesions developed in association with saddling, as the horses entered training around the 
age of 1.5-2 years. However, there appears to be variation in the severity of the disease 
with some horses developing signs shortly after birth.5  
HERDA is an autosomal recessive connective tissue disorder with affected 
progeny (homozygotes) inheriting one copy of the genetic defect from the sire and the 
other copy from the dam.2,6,7  Horses that inherit only one copy of the gene from either 
the sire or the dam never show clinical signs of HERDA and are considered to be 
‘carriers’.  These asymptomatic heterozygotes are a source for the propagation of the 
HERDA trait.  Although a point mutation in the peptidyl-prolyl isomerase B gene (PPIB) 
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coding for cyclophilin B is associated with HERDA and is used to identify carrier and 
affected horses,8 the method by which this mutation causes the clinical signs of HERDA 
is not yet documented. Tryon and colleagues have estimated the allelic frequency of the 
mutant PPIB allele to be 0.021 in the Quarter Horse population, with a disproportionate 
presence of cutting horses.9  Horses consanguineous for the prolific sire Poco Bueno 
(AQHA 3044) have a 58x greater risk of developing HERDA when compared to other 
Quarter Horse lineages.2  This is problematic because this bloodline is highly desirable in 
various equestrian disciplines, particularly cutting, and increases the chances of  breeding 
two horses that carry the HERDA trait.2  A number of obligate carriers have contributed 
disproportionately to the breeding population of Quarter Horses allowing the HERDA 
trait to propagate.  Currently the carrier rate is estimated to be 28% in elite cutting horse 
lines.10  Further, the large economic value of the affected bloodlines may prove for some 
a disincentive to responsibly identify carriers. Accordingly, in 2009 the AQHA mandated 
DNA testing to identify the mutant PPIB allele in all horses tracing to Poco Bueno or his 
dam Miss Taylor. Horses homozygous for the PPIB mutation cannot be registered with 
the AQHA.  
The homozygosity mapping experiments that identified the PPIB mutation in 
horses with HERDA identified a common haplotype across the q arm of equine 
chromosome one (ECA1q) in sixty-four of the sixty-eight horses originally diagnosed as 
affected by HERDA.11  Horses with this haplotype were also found to have four 
homozygous DNA markers in common, two of which code for a missense mutation of 
PPIB.  The first mutation identified as an adenine to guanine at position 17 in the coding 
sequence (c.17A>G) and predicted to cause a glutamic acid to glycine substitution at 
position 6 (p.6E>G) in the signal sequence of the translated protein was not considered 
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significant as it is common in the Quarter Horse breed.  The putative identifying mutation 
for HERDA was a guanine to adenine mutation at position 115 (c.115G>A) in the coding 
sequence which is predicted to cause a glycine to arginine (p.39G>R) substitution at 
position 39 in the translated protein.  The wild type c.115G in PPIB is highly conserved 
across all vertebrates.  
Central to the purpose of  investigations presented here is the fact that a causal 
association between the c.115G>A PPIB mutation and HERDA has not been 
established.8  Problematic is the absence of these mutations in 4 of the 68 horses 
originally identified as the HERDA reference population.  Of these four horses, one was 
dismissed as an inaccurate diagnosis with a justification that the horse had “begun 
training for performance events”, one horse possessed the atypical genotype upon re-
testing, and two horses were not available for follow up.  However, clinical diagnosis of 
HERDA can be difficult in less severe cases.4 In addition, the region of the genome 
identified as identical by descent on ECA1q could only be refined in fine structure 
mapping to 2.5 Mb with the available equine single nucleotide polymorphisms.  Based 
upon sequence comparisons to primates, mouse, dog, and cow, this region of large 
linkage disequilibrium was reported to contain approximately 20 genes.   
Rationale for the c.115G>A PPIB mutation as a putative causal mutation of 
HERDA is derived from the activities of the coded protein Cyclophilin B.  Cyclophilin B 
has conventionally been viewed as the primary rate limiting peptidyl-prolyl cis trans 
isomerase in fibrillar collagen synthesis.12  In this role, CyPB is thought to accelerate the 
folding of collagen by catalyzing the isomerization of peptidyl-proline bonds, making this 
protein a logical candidate gene for the histological characteristics of HERDA.  More 
recently CyPB has been shown to form an intracellular collagen-modifying complex with 
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cartilage associated protein (CRTAP) and prolyl-3-hydroxylase-1 (P3H1) which 3-
hydroxylates proline at position 986 (P986) in the alpha1 chains of type I and type II 
collagen.13,14  Mutations in any of these three genes have been shown to decrease P986 
hydroxylation and cause severe or lethal autosomal recessive osteogenesis imperfect 
(OI).13-16  OI is a disorder characterized by osteoporosis, bone fragility, and fractures that 
may be accompanied by bone deformity, tooth malformations, short stature, and 
shortened life span.  PPIB mutation and total absence of CyPB have been shown to 
induce severe OI in both humans13 and genetically altered mice17, respectively.  
However, the presumed role of PPIB in P986 hydroxylation, and cis-trans isomerization 
of proline residues and associated collagen folding has been recently questioned by a 
homozygous start codon mutation of PPIB identified in human siblings that prevents 
translation.18  The OI phenotype of these individuals lacks rhizomelia (shortening of the 
proximal portions of the limbs) and collagen from these individuals is both normally 
folded and has normal P986 hydroxylation suggesting that CyPB is not the exclusive 
peptidyl-prolyl cis-trans isomerase that catalyzes the rate-limiting step in collagen 
folding, and is not required for P986 hydroxylation as is currently thought.  While the 
role of PPIB in collagen synthesis clearly requires clarification, it is relevant that bone 
fragility has not been demonstrated in HERDA horses which possess the c.115G>A PPIB 
mutation.   
Despite its distinction from OI, HERDA does share clinical similarities with other 
diseases in the heterogeneous group of human inherited connective tissue disorders 
termed, Ehlers-Danlos syndrome (EDS), particularly those diseases characterized by 
loose, hyperextensible, and easily torn skin.15,16,19  The human syndrome is genetically 
diverse and similar conditions have been described in domestic and laboratory animals 
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including cattle, dogs, rabbits and cat.1,6,20-24  Diseases in the EDS complex have been 
classified by genetic, clinical and biochemical characteristics.15  EDS VI is an autosomal 
recessive disorder caused by defective hydroxylation of lysine residues on procollagen 
peptides.25  EDS VI patients, therefore, have decreased hydroxylysine residues that are 
essential for forming covalent pyridinium crosslinks, specifically pyridinoline (PYD) and 
deoxypyridinoline (DPD) (also termed hydroxylyslpyridinoline and lyslpyridinoline, 
respectively), that give collagen its tensile strength.8,26-28  Pyridinoline, the predominant 
pyridinium crosslink found in normal individuals, results from three hydroxylysine 
residues.29  In contrast, deoxypyridinoline requires only two hydroxylysine residues and 
one lysine residue.29  When compared to normal individuals, patients with EDS VI (Type 
A) have reduced total pyridinium crosslinks in skin, cultured skin fibroblasts, and urine 
with deoxypyridinoline levels far exceeding pyridinoline.30,31   Consequently, the ratio of 
deoxypyridinoline:pyridinoline is markedly increased. 
Clinical parallels between HERDA and the Ehlers-Danlos Syndrome (EDS) 
prompted our laboratory to investigate a possible role for defective hydroxylation of 
collagen lysine residues, which are critical to the formation of collagen pyridinium 
crosslinks, specifically in EDS VIA.  The pyridinium crosslinks, pyridinoline (PYD) and 
deoxypyridinoline (DPD), are the intermolecular bonds of collagen.19  In normal 
individuals, PYD is the predominant type I collagen crosslink.19  Our laboratory has 
demonstrated that the ratio of DPD to PYD in the urine of horses with HERDA is 
significantly elevated when compared to normal horses.32  Furthermore, this assay is 
diagnostically valid for the identification of horses with HERDA.  The mean ratio 
difference in the urine DPD:PYD ratio between affected and control horses was 2.48.  
The 95% CI for the difference between the means was as follows: 2.3, 2.67.  In humans, 
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similarly elevated urine DPD:PYD levels are diagnostic of human EDS Type VIA, which 
results from defective activity of collagen lysyl hydroxylase.19   
Patients with Ehlers Danlos Syndrome Type VI fall into two categories.  In Type 
VIA, the most common form, the biologic activity of the enzyme lysyl hydroxylase (LH)-
1 which is coded for by the gene procollagen-lysine, 2-oxoglutarate 5-
dioxygenase(PLOD)-1 is decreased.33  To date more than 20 mutations causing EDS VIA 
have been characterized in the PLOD1 gene.33-35  The second form of EDS VI, Type VIB, 
reflects a phenotypic classification based largely upon clinical parameters.  These 
individuals have normal biologic activity of the enzyme LH using in vitro assays and 
normal urine DPD:PYD ratios.36  One patient with EDS VIB had fewer hydroxylysine 
residues in collagen relative to the normal cohort.8  The evolving identification of 
multiple LH isoenzymes (enzymes with similar activity and function coded by different 
genes or portions of genes), including LH1, LH2, its splice variants LH2a and LH2b, as 
well as LH3 may provide insight into the disparity in LH activity in Type A vs. Type B 
EDS VI. In contrast to EDS VIA, three EDS VIB patients have normal LH1 mRNA 
synthesis with decreases in one or both of the LH2 and LH3 isoenzymes.36  Accordingly, 
in vitro assays of LH activity appear to be insensitive to decreases in the biologic activity 
of LH2 or LH3 and more reflective of LH1 activity, accounting for the normal LH 
activity in the face of clinical signs in EDS VIB patients. Though there is still debate, at 
this juncture a growing body of evidence suggests that the primary enzyme responsible 
for hydroxylation of lysine residues within the triple helices of the collagen molecule 
(that serve as substrates for pyridinium crosslink formation) is LH1.  Furthermore, 
hydroxylation of the lysine residues on the ends of adjacent collagen molecules (ends of 
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the collagen molecule are termed telopeptides) may be dependent upon the activity of 
other isoenzymes of LH.37  
Our co-investigators recently demonstrated that the tensile strength of skin from 
HERDA horses is decreased relative to that of unaffected control horses.38  This 
investigation evaluates the hypothesis that observed experimental and clinical evidence of 
skin fragility in HERDA result from alterations in the intermolecular crosslinks 
responsible for the tensile strength of dermal collagen, specifically pyridinoline (PYD) 
and deoxypyridinoline (DPD).  Differences in these parameters associated with skin 
healing are also evaluated.  The biochemistry of dermal collagen pyridinium crosslinking 
is assessed by comparing lysine, hydroxylysine, DPD and PYD concentrations as well as 





MATERIALS AND METHODS 
Animal Tissues: 
Animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC).  Skin samples for experiment #1 were aseptically obtained 
following sedation with detomidine (0.004 mg/kg) and butorphanol (0.004 mg/kg) from 
21 horses including 6 horses with HERDA, 6 HERDA carriers, and 9 control horses 
lacking the HERDA trait.  A portion of the study population in experiment #1 predated 
the availability of DNA testing.  For these horses HERDA was confirmed based upon the 
presence of severe lesions in animals that were consanguineous for Poco Bueno within 8 
generations.  Severe dermatologic manifestations of the disease were characterized as 
subcutaneous hematomas, open wounds, and hypertrophic scars, associated with contact 
trauma.  Both carrier and control horses lacked clinical manifestations of dermatologic 
disease.  All carrier horses were positively identified as heterozygous for the PPIB 
mutation. HERDA was excluded from the control population by either breed selection (1 
Arabian, 1 Tennessee Walking Horse, and 1 Thoroughbred), absence of implicated 
lineage (3 American Paint Horses) or absence of PPIB by DNA testing (6 horses of 
Quarter Horse descent). PPIB testing was performed courtesy of Dr. Nena Winand, 
Cornell University.  HERDA affected individuals were Quarter Horses ranging from 19-
48 months of age (mean: 34.8 months), consisting of 3 geldings, 2 stallions, and one 
female. HERDA carriers consisted of 4 Quarter Horses and 2 Quarter 
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Horse/Thoroughbred crosses and ranged from 4-14 months (mean: 5.6 months), 
consisting of 1 gelding and 5 stallions.  Control horses ranged from 30-288 months of age 
(mean: 123 months), consisting of 7 geldings, 2 stallions, and 1 female.  The ratio of 
DPD : PYD in the urine of the control and HERDA affected group was also evaluated, 
and consistent with our prior findings, horses with HERDA had significantly higher 
ratios (>2.0).2 
In experiment #2, a subset of horses from experiment #1 consisting of 3 HERDA affected 
horses and 3 control horses were also biopsied in regions of the skin that either contained lesions 
representative of HERDA, or evidence of scarring in the case of controls, respectively.  Mature 
scars were selected in control horses for comparisons to mature scars in HERDA skin because 
both samples would be reflective of collagen biochemistry associated with skin healing.  Three 
HERDA horses with lesion biopsies ranged in age from 19-43 months and included one stallion, 
one gelding and one female. Control horses with scarred skin included an American Paint Horse 
gelding, a Quarter Horse/Thoroughbred cross gelding, and a Quarter Horse female. The age range 
for scarred controls was 48-268 months. 
Skin Hydrolysates: 
Skin samples were incubated overnight in 4 ml of 2M NaBr solution to remove 
subcutaneous fat, epidermis, and hair. Once the dermis was isolated the samples were 
hydrolyzed at 150°C under vacuum for 16 hours in 6M HCl.39  Portions of the resultant 




Pyridinium Crosslink Quantification: 
Extraction of the pyridinium cross-links, DPD and PYD, from the hydrolysates 
was performed according to established procedures.30,31,39,40  Briefly, 500 ul of 
hydrolyzed dermis was fractionated on a freshly prepared cellulose column (2.5 ml of 5% 
CF-1 slurry in a solution of 7.3 M 1-butanol and 2.9 M glacial acetic acid in Nanopure 
water).  Pyridinium crosslinks, PYD and DPD, were eluted with Nanopure water, 
lyophilized, reconstituted with 1% heptafluorobutyric acid and analyzed by reverse-phase 
high pressure liquid chromatography (HPLC) on a Waters HPLC System 625, equipped 
with a fluorescence detector with excitation at 297nm and emission at 395 nm.  
Pyridinium cross-links were separated on a Waters Nova-Pak C18 column (4µm; 15cm x 
3.9mm) protected by a Waters Sentry Guard Column (Nova-Pak C18; 4µm; 2cm x 
3.9mm).39  Eluant A was 0.01M n-heptafluorobutyric acid (HFBA) in 100% water.  
Eluant B was 0.01M n-heptafluorobutyric acid in 100% acetonitrile.  The column was 
equilibrated in 82% A and 18% B; the samples were eluted with the same isocratic 
gradient at a flow rate of 1 ml/min for 22 min.  The column was then stripped with 100% 
B for 5 min and re-equilibrated with 82% A and 18% B before the next injection.  PYD 
and DPD in skin hydrolysates were identified by comparison and co-elution with 
commercial reference standards.  
Amino Acid Quantification: 
Amino acid concentrations in the dermal hydrolysates were determined using a 
Biochrom 20 Plus amino acid analyzer.  Briefly, 200 ul of dermal hydrolysate were dried 
under nitrogen, resuspended in 1 ml of HPLC grade water, lyophilized, and then 
resuspended in 200 ul of loading buffer (lithium citrate pH 2.2, Biochrom product # 80-
2038-10). Samples were analyzed as a 1:22 and 1:100 dilution in a mixture containing 50 
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ul of internal standard (500 μmol/l S-(2-aminoethyl)-L-Cysteine) and loading buffer. 
Collagen content of each sample was extrapolated from the measured hydroxyproline 
concentrations where the mass of collagen is seven and a half times the measured 
hydroxyproline mass and the molecular mass of hydroxyproline is 300,000.29  PYD, 
DPD, hydroxylysine, and lysine concentrations were normalized to collagen content for 
intersample comparisons. 
Statistical Analysis: 
Statistical analyses were implemented in SAS® System for Windows, Version 
9.1.3.  Descriptive statistics for each variable (PYD, DPD, Total Crosslinks, DPD: PYD, 
Lysine, and Hydroxylysine) were determined using the UNIVARIATE procedure with 
normality assigned using the Kolmogorov-Smirnov statistic. Data were analyzed to 
assess the relative efficacy of the treatment (lesion, nonlesion, HERDA, carrier, or 
control) by using a non-parametric one way ANOVA (NPAR1WAY) procedure where 
the data were not normally distributed or of unequal variance to provide the 
nonparametric analysis. The general linear model (GLM) procedure was employed where 
the data were normally distributed to provide the analysis of variance. Post hoc analysis 
was performed using the least square (LS) means test to determine the differences 
between treatments when statistically significant differences (p<0.05) were identified by 
NPAR1WAY or GLM. This is the first paragraph of your text.  Please note that 
paragraphs are indented automatically, so you can just hit the Enter key at the end of a 





Experiment 1 contrasted the pyridinium crosslink, lysine and hydroxylysine 
concentrations in the dermal collagen of 3 groups of horses: HERDA homozygotes, 
HERDA carriers, and control horses lacking the HERDA trait.  Data are represented 
graphically for the concentrations of PYD, DPD, total pyridinium crosslinks, as well as 
the DPD:PYD ratio in Figures 1-4, respectively.  Horses with HERDA had greater 
concentrations of DPD (x=99.4 + 49.8 pmol/nmol collagen), and a higher DPD:PYD  
ratio (x=4.01 + 0.68) in dermal collagen than carrier (DPD: 17.2+ 6.39 pmol/nmol 
collagen; DPD:PYD ratio x=0.36 + 0.2) or control horses (DPD: x=36.1 + 22.3; 
DPD:PYD: x=0.37 + 0.05) and these differences were highly significant  (DPD: p=0.001 
for affected vs. carrier, p=0.007 for affected vs. control;  DPD:PYD: p<0.0001 for 
affected versus normal or carrier).  Conversely, horses with HERDA also demonstrated 
significantly lower concentrations of PYD (x=23.8 + 9.32 pmol/nmol collagen) than 
carrier (PYD: x=60.1 + 36.1 pmol/nmol collagen) or control horses (PYD: x=80 + 30.7 
pmol/nmol collagen).  Despite the significant increase in DPD concentration and decrease 
in PYD concentration observed in the dermal collagen of HERDA horses, total 
pyridinium crosslink concentrations were not significantly different between groups 
(HERDA: x=123.2 + 59 pmol/nmol collagen; Control x=101.7 + 56 pmol/nmol collagen; 
Carrier: horses x=77.27 + 37.3 pmol/nmol collagen).  In contrast to the differences 
identified in comparisons to HERDA affected horses, PYD, DPD, and total pyridinium 
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crosslink concentrations were not significantly different between carrier and control 
groups.  The DPD:PYD ratio in carrier vs. control horses was also equivalent (carrier: 
x=0.36 +  0.20 ; control: x=0.37 + 0.05).  These results indicate that despite equivalent 
total pyridinium crosslink concentrations in HERDA, carrier, and controls, horses with 
HERDA have greater concentrations of DPD, and lower concentrations of PYD which 
collectively contribute to a marked elevation in the DPD:PYD ratio.  Whereas, PYD, 
DPD, total pyridinium crosslinks, and the DPD:PYD ratio do not differ between HERDA 
carriers and control horses. 
 
 
Figure 3.1 Pyridinoline concentrations (pmol/nmol collagen) from 6 HERDA affected, 
6 HERDA carriers and 9 control horses.  Statistically significant 
differences between groups are denoted by letters A (affected), B (control) , 





Figure 3.2 Deoxypyridinoline concentrations (pmol/nmol collagen) from 6 HERDA 
affected, 6 HERDA carriers and 9 control horses.  Statistically significant 
differences between groups are denoted by letters A (affected), B (control) , 
and C (carrier)  above the box plots (p≤0.05). 
 
 
Figure 3.3 Total Pyridinium Cross-link concentrations (pmol/nmol collagen) from 6 
HERDA affected, 6 HERDA carriers and 9 control horses.  Statistically 
significant differences between groups are denoted by letters A (affected), 




Figure 3.4 The ratio of Deoxypyridinoline to Pyridinoline from 6 HERDA affected, 6 
HERDA carriers and 9 control horses.  Statistically significant differences 
between groups are denoted by letters A (affected), B (control) , and C 
(carrier) above the box plots (p≤0.05). 
Hydroxylysine, a key substrate for the formation of pyridinium crosslinks, is 
synthesized during post-translational modifications of lysine residues in procollagen by 
the action of lysyl hydroxylase-1.  We identified a highly significant decrease in 
hydroxylysine concentrations of dermal collagen from HERDA horses (x=8.46 + 0.96 
nmol/nmol col) relative to that of carrier (hydroxylysine: 22.18 + 2.36 nmol/nmol col, 
p<0.0001) or control horses (hydroxylysine: 19.01 + 1.53 nmol/nmol collagen, 
p<0.0001).  This data is represented graphically in Figure 5.  Elevations in hydroxylysine 
concentrations of carrier relative to control horses were also significant (p=0.0017).  
Lysine concentrations in dermal collagen (Figure 6) of HERDA horses (x= 131.25 + 15.8 
nmol/nmol collagen) were significantly lower (p=0.041) than carrier horses (x= 152.57 + 
21.6 nmol/nmol collagen) and higher than controls (x= 118.44 + 14.1 nmol/nmol 
collagen).  Though the latter difference was not statistically significant, the higher lysine 
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Figure 3.5 Hydroxylysine concentrations (nmol/nmol collagen) from 6 HERDA 
affected, 6 HERDA carriers and 9 control horses.  Statistically significant 
differences between groups are denoted by letters A (affected), B (control) , 





Figure 3.6 Lysine concentrations (nmol/nmol collagen) from 6 HERDA affected, 6 
HERDA carriers and 9 control horses.  Statistically significant differences 
between groups are denoted by letters A (affected), B (control) , and C 
(carrier)  above the box plots (p≤0.05). 
Experiment 2 contrasted the pyridinium crosslink, lysine, and hydroxylysine 
concentrations associated with healing of skin lesions by quantifying these variables in 
skin derived from two regions of the same horse (Figures 7-12).  The first region, referred 
to as nonlesion (NL), appeared visually normal at biopsy. The second region, referred to 
as lesion (L) contained evidence of either a healed HERDA lesion for HERDA affected 
horses, or scarring in control horses.  Nonlesion data from both HERDA affected and 
control horses was a subset of the data previously described and intergroup comparisons 
for the variables of PYD, DPD, total pyridinium crosslinks, DPD:PYD, lysine and 
hydroxylysine were in agreement with the previously identified results.  Specifically 
relative to control horses, dermal collagen from HERDA horses had significantly greater 
concentrations of DPD, a highly significant increase in the DPD:PYD ratio, significantly 
lower concentrations PYD, and a highly significant decrease in hydroxylysine 
concentrations.  Total pyridinium crosslink concentrations were not significantly different 
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in the dermal collagen derived from nonlesioned skin of HERDA and control horses. 
However, unlike the parent group from which this subset of HERDA and control horses 
was derived, elevated lysine concentration in the dermal collagen of HERDA horses 
relative to controls reached statistical significance (p=0.0368). 
 
 
Figure 3.7 Average pyridinoline concentrations (pmol/nmol collagen) from lesion and 
nonlesion skin of HERDA affected horses and control horses.  Error bars 
represent the standard error of the mean. Statistically significant difference 
between HERDA and control groups denoted by letters A (HERDA lesion), 
B (control lesion), C (HERDA nonlesion) and D (control nonlesion) above 





Figure 3.8 Average deoxypyridinoline concentrations (pmol/nmol collagen) from 
lesion and nonlesion skin of HERDA affected horses and control horses.  
Error bars represent the standard error of the mean.  Statistically significant 
difference between HERDA and control groups denoted by letters A 
(HERDA lesion), B (control lesion), C (HERDA nonlesion) and D (control 





Figure 3.9 Average total pyridinium cross-link concentrations (pmol/nmol collagen) 
from lesion and nonlesion skin of HERDA affected horses and control 
horses.  Error bars represent standard error of the mean. Statistically 
significant difference between HERDA and control groups denoted by 
letters A (HERDA lesion), B (control lesion), C (HERDA nonlesion) and D 





Figure 3.10 The average ratio of deoxypyridinoline to pyridinoline from lesion and 
nonlesion skin of HERDA affected horses and Control horses.  Error bars 
represent the standard error of the mean. Statistically significant difference 
between HERDA and control groups denoted by letters A (HERDA lesion), 
B (control lesion), C (HERDA nonlesion) and D (control nonlesion) above 





Figure 3.11 Average hydroxylysine concentration (nmol/nmol collagen) from lesion 
and nonlesion skin of HERDA affected horses and control horses.  Error 
bars represent the standard error of the mean. Statistically significant 
difference between HERDA and control groups denoted by letters A 
(HERDA lesion), B (control lesion), C (HERDA nonlesion) and D (control 





Figure 3.12 Average lysine concentrations (nmol/nmol collagen) from lesion and 
nonlesion skin of HERDA affected horses and control horses.  Error bars 
represent the standard error of the mean. Statistically significant difference 
between HERDA and control groups denoted by letters A (HERDA lesion), 
B (control lesion), C (HERDA nonlesion) and D (control nonlesion) above 
the bars (p≤0.05). 
Comparisons of dermal collagen derived from lesion and non lesion areas of 
control horses (Figures 7-12) indicate that healing of skin is associated with a decrease in 
PYD concentrations (NL: 110.0 7 + 32.17 pmol/nmol collagen; L: 68.11 + 30.26 
pmol/nmol collagen) which approximated significance (p=0.0525) and a significant 
increase in hydroxylysine concentrations (NL: 17.9 + 1.54 nmol/nmol collagen; L: 21.52 
+ 1.81 nmol/nmol collagen, p=0.0137).  Concentrations of DPD (NL: 43.13 + 10.55 
pmol/nmol collagen; L:26.9 +  12.07 pmol/nmol collagen ), total pyridinium crosslinks 
(NL: 153.2 + 42.72 pmol/nmol collagen ; L: 95.01 + 42.31 pmol/nmol collagen), lysine 
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(NL: 105.48 + 6.29 nmol/nmol collagen; L: 126.76  + 15.59 nmol/nmol collagen), and 
DPD:PYD ratio (NL:0.40 + 0.02; L: 0.40 + 0.01) did not differ significantly between 
lesion and nonlesion skin of control horses.  In contrast, comparisons of lesion and non 
lesion skin from HERDA horses identified a significant decrease in DPD concentrations 
(NL: 133.66 + 40.28 pmol/nmol collagen; L: 38.32 + 28.39 pmol/nmol collagen; 
p=0.002), an associated  significant decrease in total pyridinium crosslink concentration 
(NL: 164.56 + 46.43 pmol/nmol collagen; L: 49.61 + 35.36 pmol/nmol collagen; 
p=0.0099), and significant decrease in DPD:PYD ratio (NL: 4.27 + 0.42; L: 3.23 + 0.44; 
p=0.003). PYD (NL: 30.9 + 6.17 pmol/nmol collagen; L: 11.29 + 6.97 pmol/nmol 
collagen), lysine (NL: 135.48 + 23 nmol/nmol collagen; L: 127.86  + 7.11 nmol/nmol 
collagen) and hydroxylysine concentrations (NL: 8.67 + 1.25 nmol/nmol collagen; L: 
8.60  + 0.085 nmol/nmol collagen) were not different between lesion and nonlesion skin 
of HERDA horses.  
Comparisons of dermal collagen from lesion skin of control horses and nonlesion 
HERDA skin (Figures 7-12) identified lower PYD concentrations in HERDA NL skin 
which approached significance (p=0.0782).  Total pyridinium crosslink concentrations 
were not significantly different between control lesion and HERDA nonlesion dermal 
collagen (p=0.0765). Relative to control lesion skin, HERDA nonlesion skin 
demonstrated highly significant elevations in DPD concentration (p=0.001), DPD:PYD 
ratio (p<0.0001) and significantly lower hydroxylysine concentrations (p<0.0001).  
Lysine concentrations were not significantly different in control lesion versus HERDA 
nonlesion skin.  
Comparisons of dermal collagen from nonlesion skin of control horses and lesion 
HERDA skin (Figures 7-12) identified in healed HERDA lesions a significantly lower 
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concentration of PYD (p=0.015) and hydroxylysine (p<0.0001), and significantly higher 
DPD:PYD ratio (p<0.0001).  Concentrations of DPD, total pyridinium crosslinks, and 






Results from this study demonstrate that despite equivalent total pyridinium 
crosslink concentrations in dermal collagen of HERDA, carrier, and control horses, 
horses with HERDA have significantly greater concentrations of DPD and significantly 
lower concentrations of PYD, which create a highly significant elevation in the 
DPD:PYD ratio relative to these parameters in carrier and control horses.  In contrast, 
concentrations of PYD, DPD, total crosslinks, and DPD:PYD ratio were not significantly 
different between carrier and control groups.  These findings in skin are consistent with 
earlier investigations of the urinary excretion of DPD and PYD in our laboratory, which 
demonstrated that relative to control or carrier horses, HERDA horses excrete 
significantly more DPD than PYD in their urine, and have an associated increase in urine 
DPD:PYD ratio (p<0.0001) that is diagnostic of HERDA.32  Thus, we conclude that 
dermal collagen from horses with HERDA has an abnormal pattern of pyridinium 
crosslinking that is reflected in the urine of HERDA horses.  
The pyridinium crosslinks, DPD and PYD are the covalent bonds responsible for 
the tensile strength of fibrillar collagen.8,26-28  Hydroxylysine is a critical substrate for 
pyridinium crosslink formation and is synthesized during post-translational modifications 
of lysine residues by the action of lysyl hydroxylase-1 (LH1) (Figure 13).19,33,37 The 
pyridinium crosslink DPD requires only two hydroxylysine residues for synthesis while 
PYD is derived from three hydroxylysine residues.  Therefore, decreased LH1 activity 
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would be expected to favor DPD production over PYD production by limiting the 
availability of hydroxylysine.  Clinical relevance of LH1 activity in collagen disorders is 
evident in human EDS VIA, collagen LH1 deficiency, where signs of skin fragility and 
kyphoscoliosis predominate.19  While skin fragility is characteristic of HERDA, we 
postulate that an absence of kyphoscoliosis in HERDA, despite pyridinium crosslinking 
that mimics kyphoscolotic EDS VIA could be explained by the quadruped orientation of 
the horse in which the head maintains the vertebral column in traction via the nuchal 
ligament.  This contrasts sharply with human bipeds where inadequate soft tissue support 




Figure 4.1 Simplified mechanism of collagen pyridinium cross-link formation.19 
 
28 
Humans with EDS VIA associated skin fragility demonstrate significant elevations in 
DPD and an elevated DPD:PYD ratio which is both sensitive and specific for EDS VIA 
diagnosis.19,41,42  By extension we propose that in HERDA the significant increase in 
DPD, which requires covalent bonds derived from two hydroxylysine residues, and 
decrease in PYD concentration which requires covalent bonds associated with three 
hydroxylysine residues, are causally associated with the syndrome of fragility and 
decreased tensile strength observed in skin from affected horses. 
To investigate the potential that decreased lysine hydroxylation in HERDA horses 
could be responsible for increased DPD formation in the skin of HERDA horses, we 
quantified lysine and hydroxylysine concentrations in dermal collagen from carrier, 
affected, and control horses.  Horses with HERDA had significantly lower hydroxylysine 
concentrations in dermal collagen relative to carrier (p<0.0001) or control horses 
(p<0.0001).  These findings mirror findings in dermal collagen of EDS VIA patients, 
namely decreased hydroxylysine content, and an associated decreased pyridinoline and 
increased deoxypyridinoline concentration.8,32,41,42 
To determine if higher lysine concentrations could be identified to support the 
theory that lysine hydroxylation was decreased in dermal collagen of HERDA, as well as 
to rule out the possibility that decreased hydroxylysine concentrations could reflect 
decreased lysine substrate, we quantified lysine concentrations in dermal collagen in 
HERDA, carrier, and control horses.  We found that the mean lysine concentration of 
HERDA horses exceeded controls by 10% (though this difference was not statistically 
significant p=0.16).  Curiously, lysine concentration of carriers was significantly higher 
than both HERDA and control horses.  This suggests that lower hydroxylysine 
concentrations in HERDA horses relative to controls do not result from decreased lysine 
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concentrations in HERDA dermal collagen.  Accordingly, other factors capable of 
decreasing hydroxylysine formation should be investigated to determine the etiology of 
decreased hydroxylysine and deoxypyridinoline concentrations that characterize dermal 
collagen of HERDA horses.  Further, the similarities between these biochemical 
characteristics of dermal collagen from HERDA and human EDS VIA supports a 
hypothesis that decreased hydroxylation of lysine residues on procollagen molecules and 
associated alterations in the profile of pyridinium crosslinks in mature collagen have a 
role in the etiopathogenesis of HERDA.  
Since HERDA is an autosomal recessive trait, the finding that hydroxylysine and 
lysine concentrations of carriers were not intermediate to those of the control group was 
somewhat unexpected.  We postulate that the significantly lower age of carrier horses in 
this study may confound this observation.  Unfortunately HERDA carriers are 
asymptomatic and their usefulness coupled with the tendency for carriers to have elite 
bloodlines limits the availability of age matched carrier controls.  The mean age of carrier 
horses was 5.6 months versus 35 months for HERDA and 123 months for control horses.  
Accordingly this is an observation that warrants further investigation.  
Differences in collagen biochemistry between HERDA and normal horses 
prompted our interest in differential effects of healing on these parameters.  In both 
HERDA and control horses, healing of skin was characterized by a decrease in DPD, 
PYD, and total crosslinks.  However, the magnitude of the decrease was greater for all 
three parameters in HERDA horses, reaching statistical significance for all crosslink 
parameters in HERDA but not controls.  In control horses the magnitude of the decrease 
in DPD and PYD, though not statistically significant, was equivalent (38%) and 
accordingly total pyridinium crosslinks also decreased by 38%.  Thus, there was no 
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change in the DPD:PYD ratio associated with healing in normal horses.  By contrast, in 
HERDA the magnitude of the decrease in DPD (71%) exceeded that of PYD (63%), 
yielding a 70% decrease in total pyridinium crosslinks, and a 25% decrease in the 
DPD:PYD ratio in HERDA.  Further, the DPD:PYD ratio associated with healing in 
HERDA horses decreased significantly, while that of controls was unchanged, indicating 
in normal but not HERDA horses the synthesis of DPD and PYD is equivalent during 
healing.  These comparisons indicate that while DPD and PYD decrease in dermal 
collagen during healing in both normal and HERDA horses, the magnitude of the 
decrease in DPD and PYD concentrations in HERDA horses significantly exceeds that of 
normal horses.  As pyridinium crosslinks provide the tensile strength of skin, we believe 
this difference in HERDA lesion pyridinium crosslinking contributes to repeated 
wounding and delayed healing of HERDA lesions, which we have observed in our 
HERDA research herd during a 6 year period. 
Quantification of lysine and hydroxylysine concentrations associated with healing 
within groups demonstrated a significant (17%) increase in the average hydroxylysine 
concentration (p=0.01) and 20% increase in average lysine concentration in control 
horses which was not statistically significant (p=0.1).  In HERDA, hydroxylysine 
concentrations were unchanged and a small (6%) but insignificant decrease in lysine 
concentration occurred in healed skin.  Thus, while healing in normal horses was 
associated with a significant increase in hydroxylysine concentration that roughly 
parallels the increase in lysine concentration, hydroxylysine concentrations are 
unchanged in HERDA during healing.  As the etiopathologic basis of HERDA is 
unknown, comparisons of lesion and nonlesion data within groups highlight that the 
biochemical composition of dermal collagen differs between healed skin of both HERDA 
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and normal horses and indicates that lesion and nonlesioned skin cannot be viewed as 
biologically equivalent in investigations of HERDA. 
Intergroup comparisons of the pyridinium crosslink and hydroxylysine 
concentrations of dermal collagen from lesions of control and HERDA horses 
demonstrate that dermal collagen from the lesions of HERDA horses have a significant 
decrease in the concentrations of PYD (p=0.015) and hydroxylysine (p<0.0001), as well 
as a highly significant increase in the DPD:PYD ratio (p<0.0001) relative to dermal 
collagen from lesions of control horses.  Though not statistically significant, DPD 
concentrations were also higher in HERDA lesion relative to control lesion groups.  
These comparisons of lesions from HERDA and control horses parallel comparisons 
previously discussed for nonlesion skin from HERDA and control horses and indicate 
that in addition to the decrease in DPD, PYD and total crosslink synthesis that 
differentiates healing in HERDA and normal horses, there also remains in HERDA 
lesions relative to control lesions, a significant decrease in PYD and hydroxylysine 
concentration, as well as an increase in DPD concentrations.  Accordingly, lesion and 
nonlesion skin of HERDA demonstrate a significant increase in DPD:PYD that is specific 
to HERDA but not normal skin.  Particularly in light of the small sample size (n=3), these 
comparisons of dermal collagen from lesion and non lesion skin are consistent with our 
hypothesis that decreased lysine hydroxylation in dermal collagen from horses with 
HERDA favors the production of DPD over PYD.  
Our findings indicate that in HERDA decreased hydroxylation of lysine residues 
in dermal collagen is associated with greater DPD and lower PYD crosslink formation 
during collagen synthesis.  LH1 is the telopeptide hydroxylase responsible for the 
hydroxylation of lysine residues that serve as substrates in pyridinium crosslink 
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formation and interactions between LH1 and PPIB have not been described. Accordingly 
a mechanism by which the PPIB mutation of HERDA could result in the combination of 
clinical skin fragility and the alterations in  hydroxylysine and pyridinium crosslink 
profile demonstrated here is not known.  Given the major role of LH1 in post-
translational lysine hydroxylation, as well as the association of LH1 deficiency in human 
EDS VIA with skin fragility, decreased lysine hydroxylation, and an increased synthesis 
of DPD, it is plausible that our parallel findings of decreased lysine hydroxylation and a 
predominance of DPD in HERDA also reflect a decrease in collagen lysyl hydroxylase 
activity.  Based upon our findings, further investigations into the defect in lysine 
hydroxylation that characterizes HERDA are warranted.  
Three functions have been ascribed to Cyclophilin B (CyPB), the protein coded 
by PPIB. First, CyPB is considered the primary rate limiting peptidyl-prolyl cis trans 
isomerase in fibrillar collagen synthesis and is accordingly considered integral to proper 
collagen folding.12  Second, CyPB is a molecular chaperone important in collagen 
synthesis, and third CyPB forms an intracellular collagen-modifying complex with 
cartilage associated protein (CRTAP) and prolyl-3-hydroxylase-1 (P3H1). This tri-
molecular complex is responsible for the hydroxylation of proline at position 986 in the 
alpha chains of type I and type II collagen.13,14   
Recent evidence suggests that hydroxylation of P986 is significant in ordered self 
assembly of collagen supermolecular structures.43  Mutations in each of the components 
of the tri-molecular complex have been associated with decreased P986 hydroxylation 
and the clinical syndrome of autosomal recessive osteogenesis imperfecta (OI), which is 
characterized by diffuse abnormal fragility of bone and sometimes accompanied by 
sensorineural hearing loss, blue sclera, dentinogenesis imperfecta, and joint 
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hypermobility.13,14,44-46  Though some references to thinning of skin occur with human 
OI, overt skin abnormalities are not clinical hallmarks of human OI.  In mice with CyPB 
deficiency associated OI, skin is hyperextensible, and has reduced stiffness, tensile 
strength, and P986 hydroxylation.17  Unfortunately, neither the status of P986 
hydroxylation of HERDA collagen nor the degree of lysine hydroxylation or pyridinium 
crosslink concentrations associated with PPIB mutation associated OI have been 
reported.  However, mutations in LEPRE and CRTAP, the two other components of the 
tri-molecular P986 hydroxylation complex, cause excessive post-translational 
modification of collagen characterized by increased lysine hydroxylation.47,48  This is 
presumed to reflect delayed collagen folding which allows increased post-translational 
modifications via LH1 and prolyl-4-hydroxylase.  The increased lysine hydroxylation of 
collagen observed with LEPRE and CRTAP mutations is in stark contrast to our findings 
in horses with PPIB mutation and HERDA.  It should be noted that in both mice and 
humans with PPIB mutations and recessive OI, excessive post translational modification 
of collagen has been documented but the nature of the overmodifications and specifically 
the presence of increased lysine hydroxylation have not been specifically reported.13,17   
Both LH1 and P3H1 belong to the family of 2-oxoglutarate/iron dependent 
oxygenases, and share conserved residues in their active sites that are also present in 
prolyl 4-hydroxylase49 (the primarily proline hydroxylase of fibrillar collagen), leading us 
to postulate that in addition to P3H1, Cyclophilin B could be important to the steric 
orientation of other members of 2-oxoglutarate iron dependent oxygenase family of 
enzymes, including LH1.  Collectively these findings indicate that a possible role for 
interactions of PPIB and LH1 cannot be ruled out and quantification of lysine 
hydroxylation, and pyridinium crosslinking in human and mouse PPIB associated OI, as 
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well as evaluation of P986 hydroxylation in HERDA would be key questions to elucidate 
whether such an interaction could explain the decreased lysine hydroxylation and 
pyridinium crosslink pattern we have identified in HERDA. 
Moving beyond the traditional framework of CyPB function for interpreting our 
results, a recent New England Journal of Medicine publication by Barnes questions the 
dogma that CyPB is a critical cis-trans prolyl-isomerase that is necessary for both P986 
hydroxylation and proper collagen folding.  The study describes human siblings with a 
homozygous start codon mutation of PPIB that prevents translation.18   The OI phenotype 
of these individuals lacks rhizomelia (shortening of the limbs) and despite one of these 
individuals being a 7 year old boy, skin of the proband was reportedly normal.  Despite 
absence of CyPB activity in these individuals, their collagen was normally folded and had 
normal P986 hydroxylation.  This study demonstrates that CyPB is not the exclusive 
peptidyl-prolyl cis-trans isomerase responsible for catalyzing the rate-limiting step in 
collagen folding and further that CyPB is not required for P986 hydroxylation. Unlike 
humans with PPIB mutation associated OI, bone fragility has not been described in 
horses with HERDA.  Given the lack of skin lesions in humans devoid of CyPB activity 
,and an inability to explain the reduced hydroxylysine and altered pyridinium crosslink 
pattern we have identified within the body of knowledge that exists for CyPB function, it 
is plausible that the PPIB mutation characterized in HERDA is identical by descent (and 
thus diagnostically valid) but not causal.    
Collectively, our findings coupled with the absence of skin signs that would be 
analogous to HERDA lesions in syndromes associated with PPIB mutations in both mice 
and humans do not provide support for the c.115G>A PPIB mutation as a putative causal 
mutation of HERDA.  Further, our results indicate that HERDA is associated with 
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decreased lysine hydroxylation and an abnormal predominance of DPD, findings that 
parallel the biochemical characteristics of  human LH1 deficiency, where skin fragility 
similar to HERDA is a clinical feature.  Our results also document that HERDA is a 
valuable animal model of altered collagen metabolism that is particularly relevant to both 
human EDS and recessive osteogenesis imperfecta, based upon the respective association 
with altered pyridinium crosslink patterns, and mutation of the PPIB gene.  Building 
upon the data presented here, future directions for HERDA research should focus on 
analyzing the metabolic pathways responsible for lysine hydroxylation in horses with 
HERDA and should investigate the systemic distribution of the observed pyridinium 
crosslink patterns.  In light of conflicting clinical and biochemical phenotypes associated 
with absence of PPIB activity in humans and mouse models, elucidating the relationship 
between the HERDA PPIB mutation, changes in pyridinium crosslink formation 
(elevated DPD, decreased PYD), and decreased hydroxylysine concentrations that we 
observed in HERDA skin will provide valuable insight into the significance of the 
reported PPIB mutation in the HERDA phenotype and the more global role  of PPIB in 
collagen metabolism.  A link between the HERDA PPIB mutation and hydroxylation of 
lysine residues that contribute to pyridinium crosslink formation (and collagen tensile 
strength) would be an entirely novel finding in collagen biochemistry.  This would not 
only refine the current understanding of the role of PPIB in collagen metabolism, but also 
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